Medical Affairs’ Role in Patient Engagement: Involvement and Importance Levels for Patient Health Outcomes, Advocacy Group, Education and Adherence Activities

STUDY OVERVIEW

As part of this evolution, Medical Affairs groups have been charged with patient engagement, bringing together caregivers, payers, healthcare professionals, and patient advocacy groups in a comprehensive environment centering on patients’ needs.

This Best Practices, LLC study informs medical leaders by benchmarking best practices in Medical Affairs’ role in patient engagement activities. Specifically, this study examines Medical Affairs’ role and responsibilities in patient engagement activities such as patient outcomes, advocacy, education and adherence.

KEY TOPICS

• Patient Health Outcomes
• Patient Advocacy Groups
• Patient Education Programs
• Patient Medication Adherence Programs

KEY METRICS

• Medical Affairs role in these patient engagement programs: patient health outcomes, patient advocacy groups, patient education, patient adherence
• Importance level for 9 listed patient health outcomes activities
• Medical Affairs involvement level for 9 listed patient health outcomes activities
• Importance level for 8 listed patient advocacy program activities
• Medical Affairs involvement level for 8 listed patient advocacy program activities
• Importance level for 10 listed patient education program activities
• Medical Affairs involvement level for 10 listed patient education program activities
• Importance level for 11 listed patient adherence activities
• Medical Affairs involvement level for 11 listed patient adherence activities

METHODOLOGY

Best Practices, LLC engaged 39 leaders from 29 biopharmaceutical companies through a benchmarking survey.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Medical Device; Chemical; Health Care


Companies Profiled:
Abbvie; Clovis Oncology; Actelion; TG Therapeutics; Alkermes; Vifor Pharma; AstraZeneca; Bayer; Biogen; Boehringer Ingelheim; cipla; Daiichi Pharmaceutical Co.; Ltd.; Genentech; Incyte; Kyowa Hakko Kirin; Medivation; Merck; MSD; Novartis; Pfizer; Roche; Sanofi Pasteur; Santen; Shire; Sunovion; Teva Pharmaceutical Industries Ltd; Theravance; Tocagen; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.